Boston, United States
Ensoma, established in 2019, is pioneering a transformative approach in the Biotechnology, Health and Wellness, and Life Sciences sectors. Operating from the United States, Ensoma focuses on developing one-time in vivo treatments that aim to precisely engineer blood and immune cells to combat diseases intrinsically.
With a compelling vision encapsulated by the slogan, "The future of medicine lies within us.", Ensoma endeavors to push the boundaries of genomic medicine, offering treatments that are as adaptable and precise as the body's own cells. Their innovative approach seeks to deliver a versatile and off-the-shelf solution to patients worldwide.
The company's latest financial milestone involves securing a significant $53.00M in a Late VC investment round on 01 September 2025. This round was backed by esteemed investors such as F-Prime Capital, 5AM Ventures, Bill & Melinda Gates Foundation, among others, reflecting strong confidence in Ensoma's potential to redefine the future landscape of medicine.
Stembio Cell and Tissue Technologies Inc.
Promethera Biosciences